1370468-36-2

Basic information

• Product Name: Elbasvir
• Synonyms: Elbasvir;Elbasvir/MK-8742
• CAS NO: 1370468-36-2
• Molecular Formula: C₄₉H₅₅N₉O₇
• Molecular Weight: 882.0171
• Mol File: 1370468-36-2.mol

Chemical Properties

• Appearance: /
• Density: 1.40±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 11.22±0.46(Predicted)
• CAS DataBase Reference: Elbasvir(CAS DataBase Reference)
• NIST Chemistry Reference: Elbasvir(1370468-36-2)
• EPA Substance Registry System: Elbasvir(1370468-36-2)

Safety Data

• Hazardous Substances Data: 1370468-36-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Elbasvir is used as an antiviral drug for the treatment of hepatitis C virus (HCV) in patients with HCV genotype 1 infection. It works by inhibiting the viral phosphoprotein NS5A, which plays a crucial role in viral replication, assembly, and secretion, thereby helping to combat the infection.

Upstream product

• 1585969-27-2 C₃₅H₃₃N₇O*ClH 
• 111398-44-8 N-methoxycarbonyl-L-valine 
• 108-43-0 3-monochlorophenol 
• 81682-38-4 2-(2-bromo-5-chloro-phenyl)acetic acid 
• 1292836-05-5 methyl ((S)-1-((S)-2-(5-bromo-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate 
• 1713286-24-8 C₁₂H₁₈ClN₃O₂ 
• 1007882-59-8 (S)-2-(4-bromo-1H-imidazol-2-yl)pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1007882-58-7 (S)-tert-butyl 2-(1H-imidazol-2-yl)pyrrolidine-1-carboxylate 
• 69610-40-8 N-(tert-butoxycarbonyl)-L-prolinol 
• 1403991-85-4 1-(4-bromo-2-hydroxyphenyl)-2-(2,5-dibromophenyl)ethanone 
• 1403991-82-1 3-bromophenyl 2-(2,5-dibromophenyl)acetate 
• 203314-51-6 (2,5-dibromo-phenyl)-acetyl chloride 
• 1585969-27-2 6-phenyl-3,10-bis(2-((S)-pyrrolidin-2-yl)-1H-imidazol-5-yl)-6H-benzo[5,6][1,3]oxazino[3,4-a]indole 
• 1585969-26-1 (2S,2'S)-di-tert-butyl 2,2'-(5,5'-((S)-6-phenyl-6H-benzo[5,6][1,3]oxazino[3,4-a]indole-3,10-diyl)bis(1H-imidazole-5,2-diyl))bis(pyrrolidine-1-carboxylate) 4-nitrobenzoic acid 

Relevant articles and documents

AN IMPROVED PROCESS FOR THE PREPARATION OF ELBASVIR AND ITS SALT THEREOF

The present invention relates to an improved process for the preparation of Elbasvir compound of Formula-I through its novel salt.

Enantioselective Synthesis of Hemiaminals via Pd-Catalyzed C-N Coupling with Chiral Bisphosphine Mono-oxides

A novel approach to hemiaminal synthesis via palladium-catalyzed C-N coupling with chiral bisphosphine mono-oxides is described. This efficient new method exhibits a broad scope, provides a highly efficient synthesis of HCV drug candidate elbasvir, and has been applied to the synthesis of chiral N,N-acetals.

PROCESS FOR PREPARING TETRACYCLIC HETEROCYCLE COMPOUNDS

The present invention is directed to a process for preparing Tetracyclic Heterocycle Compounds of formula (I): which are useful as HCV NS5A inhibitors. The present invention is also directed to compounds that are useful as synthetic intermediates for making the compounds of formula (I).

Enantioselective synthesis of an HCV NS5a antagonist

A concise, enantioselective synthesis of the HCV NS5a inhibitor MK-8742 (1) is reported. The features of the synthesis include a highly enantioselective transfer hydrogenation of an NH imine and a dynamic diastereoselective transformation. The synthesis of this complex target requires simple starting materials and nine linear steps for completion.

Discovery of MK-8742: An HCV NS5A inhibitor with broad genotype activity

The NS5A protein plays a critical role in the replication of HCV and has been the focus of numerous research efforts over the past few years. NS5A inhibitors have shown impressive in vitro potency profiles in HCV replicon assays, making them attractive components for inclusion in all oral combination regimens. Early work in the NS5A arena led to the discovery of our first clinical candidate, MK-4882 [2-((S)-pyrrolidin-2-yl)-5-(2-(4-(5-((S)-pyrrolidin- 2-yl)-1H-imidazol-2-yl)phenyl)benzofuran-5-yl)-1H-imidazole]. While preclinical proof-of-concept studies in HCV-infected chimpanzees harboring chronic genotype 1 infections resulted in significant decreases in viral load after both single- and multiple-dose treatments, viral breakthrough proved to be a concern, thus necessitating the development of compounds with increased potency against a number of genotypes and NS5A resistance mutations. Modification of the MK-4882 core scaffold by introduction of a cyclic constraint afforded a series of tetracyclic inhibitors, which showed improved virologic profiles. Herein we describe the research efforts that led to the discovery of MK-8742, a tetracyclic indole-based NS5A inhibitor, which is currently in phase 2b clinical trials as part of an all-oral, interferon-free regimen for the treatment of HCV infection. Effective treatment of chronic hepatitis C with direct-acting antivirals will require combination therapy with multiple agents that target different steps in the viral replication cycle and impose a high barrier to resistance. MK-8742 is a potent inhibitor of hepatitis C virus non-structural protein 5A (HCV NS5A) that is being developed as a component of an once-daily, all-oral, interferon-free regimen for the treatment of chronic HCV infection. Copyright

TETRACYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to novel Tetracyclic Indole Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, A', G, R1, R15, U, V, V', X, X', Y and Y' are as defined herein. The present invention also relates to compositions comprisingat least one Tetracyclic Indole Derivative, and methods of using the Tetracyclic Indole Derivatives for treating or preventing HCV infection in a patient.

TETRACYCLIC INDOLE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION

Tetracyclic indole derivatives of formula (I), pharmaceutically acceptable salts and the pharmaceutical compositions thereof are provided, wherein A, A', G, R1, R15, U, V, V, W, W, X, X', Y, Y' are as defined in the invention. Use of these derivatives for treating hepatitis C virus (HCV) infection is also provided.